Welcome to NDA’s free Breakfast seminar on Thursday 14th March 09:00- 10:30 on Immunogenicity for investigational biopharmaceutical products – Start with the goal in mind
All biopharmaceutical products are associated with an intrinsic potential to induce immune responses in treated subjects. Regulatory agencies expect sponsors to evaluate and mitigate these risks during product development, applying a strategy that addresses product- and patient-related factors. Overall, understanding and controlling immunogenicity-related risks are attainable objectives, and approvability should not be compromised if these risks are suitably evaluated from the earliest stages of development.
Join us to hear Paul Chamberlain, Biopharmaceuticals & Immunogenicity Expert and NDA Advisory Board member, explain how to anticipate and avoid issues for biopharmaceutical development. Grab this opportunity to benefit from his experiences and insights.
- How to apply immunogenicity risk assessment at the lead candidate selection stage
- Minimizing incremental risks associated with manufacturing
- Understanding what and how to evaluate, at different stages of clinical development
- Integrated presentation of data to regulatory agencies
When: Thursday 14th March 2019, breakfast from 09:00, presentations start at 09:30
Where: Am Klopferspitz 19a, 82152 Martinsried/Planegg, BioM Seminarraum, Munich, Germany
The Breakfast seminar will be an open and interactive workshop with the opportunity to ask questions to Paul. Questions can also be sent in advance to email@example.com. Please specify if you would like to ask them openly during the seminar or prefer to discuss them privately afterwards.
Registration: By Tuesday 12th March 2019 to: firstname.lastname@example.org
Contact: Nathalie Brodale-Breinbauer, +49 (0) 89 3585 4036 or email email@example.com
We look forward to seeing you there!